Print this article

Avecia Capacity Expansion 3000+

Keywords:

e-version image

Click HERE to download the PDF version

 

Nitto Avecia (Avecia) has strategically eliminated the shortage of oligonucleotide manufacturing capacity available to our clients globally. The combined oligonucleotide manufacturing capacity in Milford MA and Cincinnati OH is now above 3000mmol. Avecia has executed this expansion strategy on its solid foundation as the leading contract manufacturing organization (CMO) in the oligonucleotide Active Pharmaceutical Ingredient (API) marketplace. In this dynamic field, Avecia continues to innovate by relying on its oligonucleotide expertise, process validation experience with 12 process performance qualifications (PPQs) completed, Regulatory compliance and commitment to providing Quality products and service to our clients.

The facility opening in August 2017 signaled the successful completion of Avecia’s newest and largest expansio ... ...


 

Teknoscienze publisher & event organiser
viale Brianza 22, 20127
Milano – Italy
info@teknoscienze.com
Tel +39 02 26809375

 

 

Subscribe now